Skip to main content
. 2021 May 21;12:666971. doi: 10.3389/fphar.2021.666971

TABLE 2.

Comparisons of the clinical and laboratory features of 21 SLE patients at different time points.

T0 (n = 21) T6 (n = 21) T12 (n = 21) p T0 vs. T6 p T0 vs. T12 p T6 vs. T12
Disease activity
SLEDAI 2K-score 6 (4–10) 4 (2–6) 4 (2–5) 0.0007 0.0025 0.9045
Laboratory Parameters
 Serum levels of C3 (mg/dl) (nv = 80–160) 72 (52–97) 74 (50–103) 73 (50–101) 0.9404 0.6789 0.6600
 Serum levels of C4 (mg/dl) (nv = 10–40) 9 (6–18) 11 (3–18) 11 (6–20) 0.3480 0.1394 0.3486
 Serum levels of anti-dsDNA (UI/ml) (nv < 7) 26 (7–128) 28 (5–228) 28 (5–110) 0.5699 0.2114 0.3396
Treatment
 Dosage of prednisone (mg/day) 9 (5–23) 6 (3.6–12.5) 4 (3–10.5) 0.0030 0.0010 0.0468

Data are expressed as median (10th–90th percentile). SLEDAI-2K score, Systemic Lupus Erythematosus disease Activity Index 2000; C3 and C4: complement factor 3 and 4; Anti-dsDNA, anti-double-stranded DNA autoantibody; nv, normal values. In bold p ≤ 0.050.